Discover 644 paid clinical trials in Milwaukee, Wisconsin. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 644
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
for
B-cell Malignancy, Chronic Lymphocytic Leukemia,
Location: Milwaukee WI, Chicago IL, Fort Wayne IN, Maumee OH,
Sponsor: Carna Biosciences, Inc.
Sex: All
Age: 18+
Code: NCT05602363
Phase1, Recruiting
Continuous Glucose Monitoring and OGTT Screen for Cystic Fibrosis Related Diabetes in Cystic Fibrosis
for
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Location: Milwaukee WI
Sponsor: Medical College of Wisconsin
Sex: All
Age: 18+
Code: NCT06560463
Recruiting
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
for
Locally Advanced Hepatocellular Carcinoma,
Location: Milwaukee WI, Ann Arbor MI, Urbana IL, Rochester MN,
Sponsor: Academic and Community Cancer Research United
Sex: All
Age: 18+
Code: NCT05168163
Phase2, Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
for
Graft-versus-host Disease (GVHD)
Location: Milwaukee WI, Madison WI, Ann Arbor MI, Indianapolis IN,
Sponsor: Incyte Corporation
Sex: All
Age: 18+
Code: NCT06615050
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
REMASTer: REcurrent Brain Metastases After SRS Trial
Location: Milwaukee WI, Chicago IL, Kettering OH, St Louis MO,
Sponsor: Monteris Medical
Sex: All
Age: 18+
Code: NCT05124912
Recruiting
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
for
Gastrointestinal Stromal Tumor (GIST),
Location: Milwaukee WI, Chicago IL, Iowa City IA, Ann Arbor MI,
Sponsor: Kura Oncology, Inc.
Sex: All
Age: 18+
Code: NCT06655246
Phase1, Recruiting
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
for
Hereditary Angioedema (HAE)
Location: Milwaukee WI, Wheaton IL, St Louis MO, Hershey PA,
Sponsor: Pharvaris Netherlands B.V.
Sex: All
Age: 12+
Code: NCT06679881
Phase3, Recruiting
Combination of TATE and PD-1 Inhibitor in Liver Cancer
for
Hepatocellular Carcinoma, Gastric Cancer
Location: Milwaukee WI, Oklahoma City OK, Orange CA
Location: Milwaukee WI, Evanston IL, Lexington KY, Greenville SC,
Sponsor: W.L.Gore & Associates
Sex: All
Age: 18+
Code: NCT04718168
Recruiting
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Improving Partnerships With Family Members of ICU Patients
for
Critical Illness
Location: Milwaukee WI, Saint Louis MO, Toronto, Hershey PA,
Sponsor: Clinical Evaluation Research Unit at Kingston General Hospital
Sex: All
Age: 55+
Code: NCT02920086
Recruiting
XTX301 in Patients With Advanced Solid Tumors
for
Advanced Solid Tumor
Location: Milwaukee WI, Saint Louis Park MN, St Louis MO,
Sponsor: Xilio Development, Inc.
Sex: All
Age: 18+
Code: NCT05684965
Phase1, Phase2, Recruiting
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
for
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma,
Location: Milwaukee WI, Iowa City IA, Cincinnati OH,
Sponsor: Caribou Biosciences, Inc.
Sex: All
Age: 18+
Code: NCT04637763
Phase1, Recruiting
Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE
for
Pregnancy Related
Location: Milwaukee WI
Sponsor: Medical College of Wisconsin
Sex: Female
Age: 18 - 65
Code: NCT05993689
Recruiting
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies